Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.
暂无分享,去创建一个
N. Jhala | W. Bell | D. Chhieng | Allyson C. Baker | T. Winokur | O. Hameed | M. Klein | A. Adams | Nicole E Balmer | Holly N Burford
[1] K. Shen,et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .
[2] D. Chhieng,et al. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma? , 2007, American journal of clinical pathology.
[3] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[4] B. Ljung,et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] Irene L Andrulis,et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.
[6] M. Hammond,et al. Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice. , 2003, Archives of pathology & laboratory medicine.
[7] Hung Chiang,et al. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. , 2002, American journal of clinical pathology.
[8] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[9] S. Ménard,et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.